E-cigarette Sales Surge by Almost 50%: CDC Data

Jun.25.2023
E-cigarette Sales Surge by Almost 50%: CDC Data
CDC data shows e-cigarette sales increased nearly 50% in three years, led by non-tobacco flavors. Sales of disposable e-cigarettes surpassed pod systems.

According to CBS News, data released by the U.S. Centers for Disease Control and Prevention (CDC) shows that e-cigarette sales have grown by nearly 50% over the past three years, increasing from 15.5 million in January 2020 to 22.7 million in December 2022.


These data come from an analysis by the Centers for Disease Control and Prevention of data from market research companies. The analysis was published in the agency's "Morbidity and Mortality Weekly Report.


One-time-use sales surpass replaceable magazine sales.


Fatma Romeh, the Chief Market Analyst at CDC, stated in a declaration that...


The significant increase in e-cigarette sales from 2020 to 2022 is primarily driven by the growth of non-tobacco flavored e-cigarettes, such as the dominance of mint flavor in the prefilled pod market and the leading position of fruit and candy flavors in the disposable e-cigarette market.


According to the national youth tobacco survey data released in 2022, more than 80% of middle and high school students use e-cigarettes with fruit or mint flavors, as pointed out by Romei.


According to data, even though disposable e-cigarettes accounted for less than a quarter of total sales in January 2020, by March 2022 disposable e-cigarette sales surpassed pod system sales.


From January 2020 to December 2022, the unit share of pod systems decreased from 75.2% of total sales to 48.0%, while the unit share of disposable e-cigarettes increased from 24.7% to 51.8%.


Sales of e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States


Sales volume of pod systems | Image source: Centers for Disease Control and Prevention in the United States.


Sales of disposable e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States.


The total number of e-cigarette brands in the market has increased by 46.2%.


According to data, the number of e-cigarette brands in the United States market is continually increasing. During the CDC study, the total number of e-cigarette brands in the US market increased by 46.2%, from 184 to 269.


Deirdre Lawrence Kittner, the Director of Smoking and Health Office at the CDC, stated in a release:


The sharp rise in e-cigarette use among teenagers in 2017 and 2018, fueled largely by JUUL, highlights the rapid evolution of sales and use patterns in the e-cigarette industry.


The overall sales growth of e-cigarettes has slowed down.


According to data, total sales increased by 67.2% from January 2020 to May 2022, rising from 15.5 million units per period to 25.9 million units. However, from May 2022 to December 2022, total sales decreased by 12.3%.


Even though overall monthly sales have been decreasing since May 2022, sales are still millions higher compared to early 2020. The CDC attributes the recent decline to several factors, including the efforts of health departments to regulate the sales of nicotine products.


At the national level, the FDA has taken multiple measures this year in an effort to curb unauthorized sales of e-cigarettes.


Director of the Center for Tobacco Products (CTP) at the FDA, Brian King, stated in a declaration that:


All participants in the supply chain, including retailers, have a responsibility to prevent illegal e-cigarettes from being placed on the market.


A previous CDC study report analyzed that the comprehensive flavor ban in Massachusetts resulted in a sharp decline of 94% in the sales of flavored e-cigarettes in the state.


It is worth noting that more and more state and local governments in the United States are also attempting to impose restrictions on the sale of flavored e-cigarettes.


As of December 31, 2022, seven states (California, Maryland, Massachusetts, New Jersey, New York, Rhode Island, and Utah) and 378 jurisdictions (including counties, cities, towns, and villages) have implemented some form of restriction on flavored electronic products.


The CDC acknowledged that other factors may also contribute to the sales slowdown, including the increase in high-dose or high-volume disposable e-cigarettes purchased at one time, resulting in more or stronger doses each time.


Moreover, this data is limited to the sales performance of traditional brick-and-mortar retailers. This suggests that some sales may not have actually declined, but instead shifted elsewhere, such as online orders or specialized e-cigarette stores not included in the company's sales data.


References:


Health officials have raised concerns about the surge in e-cigarette sales, which have coincided with a rise in calls to poison control centers.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
JT Plans ¥800 Billion Investment in Heated Tobacco Over Three Years, Betting on Ploom as Second Growth Engine
JT Plans ¥800 Billion Investment in Heated Tobacco Over Three Years, Betting on Ploom as Second Growth Engine
Japan Tobacco Inc. (JT) CEO Takehiko Tsutsui said the company plans to invest about ¥800 billion (approximately US$5.4 billion) in heated tobacco products over three years through 2028, aiming to establish Ploom as a second growth engine after combustible cigarettes. Tsutsui said Ploom AURA helped JT increase its share of Japan’s heated tobacco market to 15.8% in the first quarter of 2026. Ploom products are now available in 29 markets, with Ploom AURA sold in 25 markets including Japan. JT also plans to continue its cigarette business while positioning its food operations, particularly frozen noodle products in North America, as another growth opportunity.
Jul.23
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03